ArticleTranslational andrology and urology2024
Unravelling the natural history of localised prostate cancer in the post-prostate specific antigen era: implications for clinical management.
Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Management of localised prostate cancer (PCa) remains controversial in the era of prostate-specific antigen (PSA) testing. This study aims to describe the natural history of men with PCa being followed up expectantly to evaluate disease mortality. Methods: After exclusion, clinical data of 204 patients retrieved from a prospective large PCa registry were reviewed. Competing risk analysis were performed using the Fine-Gray model. Results: The median age was 73 years old with a median follow up of 12.5 years. The median PSA was 8.85 ng/mL and the risk stratification were as follows: low (47.0%), intermediate (31.4%), and high risk (21.6%). There were 19 PCa (9.3%) and 84 non-PCa deaths (41.2%), with overall mortality at 50.5%. Multivariate analysis showed patients with high PSA values [subdistribution hazard ratio (sdHR) 7.13], poorer prostate cancer grade groups (PCGG) (sdHR 16.349), and therefore higher European Association of Urology risk group (sdHR 11.42) had greatly elevated prostate cancer mortality (PCM). Older patients greater than 75 years of age (sdHR 4.52) and high Charlson Comorbidity Index (CCI ≥6) scores had higher non-prostate cancer mortality (NPCM) (sdHR 7.87). Subgroup analysis of the high-risk group showed having a lower CCI score (≤3) had a greater risk of PCM than NPCM (sdHR 4.31 Conclusions: Overall PCM remains low in elderly men with conservatively treated PCa. Age and poorer CCI predict NPCM while PSA and PCGG predict PCM. In high-risk PCa group, CCI is a useful tool to determine which patients will benefit from radical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.